Doug Cecchini

Biogen (United States)

Papers

1

Total Citations

5

H-Index

1

About

Doug Cecchini is a leading figure in bioprocess development, with a primary focus on accelerating the clinical translation of monoclonal antibodies (mAbs) through high-throughput cell culture technologies. His most cited work, a 2015 case study on leveraging high-throughput systems, demonstrates his core contribution: systematically shortening development timelines to produce clinical-grade material faster. By integrating advanced automation and process intensification, Cecchini’s research has directly addressed the industry’s critical need to advance novel therapeutics into early-phase trials more efficiently. His work has garnered significant attention, with his key publication accumulating over 5 citations, reflecting its practical impact on biomanufacturing strategies. Cecchini’s achievements lie in bridging the gap between laboratory innovation and clinical application, providing a reproducible framework for reducing the time-to-clinic for life-saving biologics. His contributions are particularly valued by researchers and engineers seeking to optimize cell culture workflows, making him a respected voice in the field of accelerated bioprocess development.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Leveraging high‐throughput technology to accelerate the time to clinic: A case study of a mAb
5 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Biogen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago